Day One Biopharmaceuticals, Inc. (DAWN)


+0.10 (+0.82%)
Symbol DAWN
Price $12.895
Beta 0.000
Volume Avg. 0.66M
Market Cap 948.906M
Shares () -
52 Week Range 5.44-28.35
1y Target Est -
DCF Unlevered DAWN DCF ->
DCF Levered DAWN LDCF ->
ROE -42.27% Strong Sell
ROA -40.73% Strong Sell
Operating Margin -
Debt / Equity 5.13% Neutral
P/E -7.01 Strong Sell
P/B 2.54 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest DAWN news

Dr. Jeremy Bender M.B.A., Ph.D.
NASDAQ Global Select

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.